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Quantification of glomerular TGF-1 mRNA in patients with
diabetes mellitus
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Quantification of glomerular TGF-1 mRNA in patients with diabetes
mellitus. Transforming growth factor-fll (TGF-131) is a primary determi-
nant of the mesangial expansion observed in diabetic nephropathy. In this
study, we quantitated the levels of intraglomerular TCF-J31 mRNA in
patients with diabetes mellitus using a competitive polymcrase chain
reaction (PCR) method. Renal biopsy specimens were obtained from 29
patients with non-insulin-dependent diabetes mellitus. Total RNA was
extracted from the glomeruli and reverse transcribed into eDNA with
reverse transcriptase. To prepare samples containing identical amounts of
f3-actin eDNA (8 pg), we performed competitive PCR by co-amplifying
mutant templates of -actin with a unique EcoRI site. We also used this
competitive PCR method to measure TGF-J31 eDNA by co-amplifying
mutant templates of TGF-pl. We observed higher expression of TGF-f31
mRNA in glomeruli of patients with diabetic nephropathy as compared
with normal glomeruli. Intraglomerular TGF-/31 mRNA was elevated,
even in the early stage of diabetic nephropathy. Moreover, levels of
intraglomerular TGF-f31 mRNA correlated with values of HhAlc. These
data suggest that hyperglycemia induces intraglomerular TGF-f31 mRNA
expression in vivo, and that TGF-1 overproduction may be associated
with the progression of diabetic nephropathy.
Diabetic nephropathy is a fatal complication of diabetes mdli-
tus and a common cause of end-stage renal disease [1]. It is
characterized histologically by expansion of the glomerular me-
sangium due to art increase in extracellular matrix (ECM) pro-
teins [2]. Although hyperglycemia plays a key role in the initiation
and progression of diabetic nephropathy, the mechanisms by
which hyperglycemia causes the histologic change remain to be
elucidated.
There have been several reports indicating that various cyto-
kines and vasoactive peptides were associated with the pathogen-
esis of diabetic nephropathy. Atrial natriuretic peptide increased
glomerular filtration rate [3]. Overproduction of platelet-derived
growth factor B (PDGF-B), tumor necrosis factor-a (TNF-a), and
basic fibroblast growth factor (bFGF), all of which are mitogenic
for cultured mesangial cells, has been observed in diabetic rats [4].
Transforming growth factor-f31 (TGF-pl) may be a primary
determinant of mesangial expansion observed in diabetic ne-
phropathy for the following reasons. Firstly, Yamamoto et al have
demonstrated enhanced expression of TGF-f31 in the glomeruli of
diabetic rats and localization of the TGF-pl protein in patients
with diabetic nephropathy by immunohistochemistry [5]. Sec-
ondly, Wolf et al have demonstrated that hyperglycemia stimulats
TGF-131 synthesis in cultured mesangial cells [61. Thirdly, Choi et
al have shown that rat mesangial hypertrophy is induced when
exposed to TGF-J31 in vitro [7].
Quantitative analysis of the glomerular mRNA encoding
TGF-f31 in cases of human diabetic nephropathy is difficult since
few renal biopsy specimens are available. Peten et al have shown
that human glomerular mRNA encoding for a2 (IV) collagen can
be measured by a competitive polymerase chain reaction (PCR)
method [81. Our previous study have also demonstrated that levels
of glomerular TGF-pl mRNA can be measured accurately by a
competitive PCR method [9]. In this study, we quantitated
glomerular expression of TGF-f31 mRNA in patients with diabetic
nephropathy to determine whether TGF-/31 plays a role in the
progression of diabetic nephropathy. Furthermore, we investi-
gated the correlation between the levels of intraglomerular
TGF-/31 mRNA and several clinical parameters.
Methods
Patients
Renal biopsy specimens were obtained from 29 patients with
non-insulin-dependent diabetes mellitus (NIDDM). All patients
gave their informed consent. Table I summarizes the clinical
characters of these patients.
We obtained control specimens from ii patients (8 males and
3 females) with renal cell cancer. The mean age of the patients
with renal cell cancer was 58 10 years (mean SD). The mean
values of creatinine clearance were 91 22 mI/mm (mean SD).
The control specimens, which consisted of the remaining normal
kidney after resections for renal cell cancer, showed only minor
changes in glomeruli by light microscopy (normal glomeruli).
Light microscopy
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Renal biopsy specimens for light microscopy were fixed in 10%
neutral phosphate-buffered formalin, embedded in paraffin and
cut into 3 tm sections. The sections were stained with the periodic
acid-Schiff reagent. Patients were divided into three groups (Dif-
fuse I to Diffuse III) based on the extent of mesangial expansion
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Table 1. Characteristics of patients
according to the Geilman's classification (Fig. 1) [10], with the
exception that the Diffuse III group in this study contained both
the Diffuse III and Diffuse IV groups defined by the Geilman's
classification.
Immunohistochemical localization of type IV collagen
Paraffin sections (4 pm) were deparaffinized and endogenous
peroxidase activity was denatured with 1% hydrogen peroxide.
After incubation for five minutes at 37°C in 0.4 mg/mi proteinase
K (Dako Japan Co., Kyoto, Japan), the sections were irradiated
with microwaves for two minutes. Sections were subsequently
incubated with 10% normal goat serum, then reacted with a
polyclonal antibody to human type IV collagen (Chemicon Inter-
national Inc., Temeula, CA, USA) for two hours at 37°C. After
washing with phosphate-buffered saline (PBS), the sections pro-
cessed further using LSAB kits (Dako). The staining intensity of
collagen type IV was graded semiquantitatively as weak (Grade I),
moderate (Grade II), and strong (Grade III).
Immunohistochemical localization of TGF-f31
Frozen sections (3 m) were fixed in cold aceton for 10 minutes
before staining. After washing with PBS, sections were reacted
with a polyclonal antibody to human TGF-/31 (King Brewing Co.,
Kakogawa, Japan) for two hours at 37°C. After washing with PBS,
the sections were incubated with fluorescein-conjugated F(ah')2
goat anti-rabbit IgG (Cappel, Malvern, PA, USA), which had
been absorbed with normal human plasma before use. For nuclear
staining, propydium iodide (Sigma, St. Louis, MO, USA) was
used. The section thus prepared was examined with a laser
confocal microscope (MRC-600, Bio-Rad, Tokyo, Japan).
Total RNA extraction and reverse transcription
Glomeruli were obtained by dissecting 10 to 20% of each of the
renal biopsy specimens under phase-contrast microscopy as de-
scribed previously [11]. We extracted total RNA from glomeruli
as described previously [91. Total RNA was reverse transcribed
into eDNA with I unit/ps of RAV-2 reverse transcriptase (Am-
ersham, Aylesbury, UK). The reaction mixture also contained 100
p of random hexamers, 1 m of dATP, dCTP, dTTP, and dGTP,
and 1 U/1id RNase inhibitor (Amersham). The reaction mixtures
was incubated at 42°C for one hour, then heated to 95°C for five
minutes to denature the RNA-cDNA hybrid and to inactivate the
reverse transcriptase.
Oligonucleotide primers
The primers were synthesized on a PCR-Mate DNA synthesizer
(Applied Biosystems, Inc., Foster, CA, USA). Human -actin
cDNA was amplified with the following primers: TGACGGGGT-
CACCCACACTGTGCCCATCTA (bases 509 to 538) as the
sense primer and ACTCGTCATACTCCTGCTTGCTGATCCA
(bases 1107-1134) as the antisense primer [121. Human TGF-f31
Patient Duration Urinary Ccr TGF-j31
number Age/sex years Complication albumin Histology mi/mm fg//pg 13-actin
1 64/M 3 normo Diffuse I 78 0.88
2 62/M 3 hypertension normo Diffuse I 96 0.25
hyperlipidemia
3 60/F 3 normo Diffuse 1 97 1.01
4 60/M 3 normo Diffuse I 76 0.54
5 62/M 3 hypertension normo Diffuse I 79 0.22
6 58/M 4 micro Diffuse I 93 2.00
7 46/F 4 hypertension micor Diffuse II 125 1.50
8 51/F 6 hypertension
hyperlipidemia
normo Diffuse II 133 1.50
9 46/F 6 normo Diffuse 1 80 0.40
10 45/M 6 micro Diffusc I 86 1.00
11 69/M 7 overt Diffuse II 45 0.70
12 62/M 8 normo Diffuse 1 83 0.40
13 55/F 9 overt Diffuse I 118 0.45
14 57/F 9 hyperlipidemia micro Diffuse III 82 1.00
15 61/F 10 hypertension normo Diffuse II 56 0.50
16 62/M 10 hypertension overt Diffuse III 89 0.25
17 64/F 11 normo Diffuse III 50 0.50
18 61/M 13 normo Diffuse I 89 1.27
19 65/M 15 hypertension normo Diffuse II 48 0.25
20 44/F 15 overt Diffuse III 36 1.25
21 68/M 16 overt Diffuse III 25 2.00
22 69/F 16 hypertension normo Diffuse II 67 0.50
23 50/M 18 overt Diffuse III 40 0.75
24 61/M 20 overt Diffuse III 48 1.53
25 69/M 20 overt Diffuse III 39 0,32
26 43/F 20 hyperlipidemia micro Diffuse III 63 0.25
27 45/F 21 micro Diffuse I 56 1.00
28 67/F 25 micro Diffuse II 143 3.00
29 67/M 30 normo Diffuse 1 90 2.00
Abbreviations are: M, male; F, female; duration, duration of disease; normo, normoalbuminuria; micro, microalbuminuria; overt, overt albuminuria;
Diffuse I-Ill are defined in Method's section; Ccr, creatinine clearance.
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Fig. 1. A glomerulus showing segmental widening of the mesangial area DiJJise I) (upper left, periodic acid-Schiff staining, X 400). Mild enlargement of the
mesangial area is observed in a diffuse pattern (Diffuse II) (upper right, periodic acid-Schiff staining, x 400). The mesangial area is increased and the
capillary wall is diffusely thickened. Some capillary lumina are reduced in size due to the mesangial enlargement (Diffuse III) (bottom left, periodic
acid-Schiff staining, >< 400). Mesangial expansion is marked. In Diffuse IV, nodules are occasionally observed (bottom right, periodic acid-Schiff staining,
x 400).
cDNA was amplified with the following primers: AGCGACTC-
GCCAGAGTGGTTATCTT (bases 1411-1435) as the sense
primer and TFATGCTGGTTGTACAGGGCCAGGA (bases
1860-1884) as the antisense primer [13]. These primers were
derived from separate exons to inhibit amplification of any
contaminating genomic DNA sequences.
Generation of competitive mutant templates
To circumvent the problem of variability in amplification effi-
ciency, competitive templates were generated by site specific
mutagenesis using two mutant primers as described by Higuchi,
Krummel and Saiki [141. Mutant primers 30 base pairs in length
contained a single base pair change which created a unique EcoRI
site in the competitive templates of the human f3-actin gene and
the human TGF-131 gene. Mutant fragments were subcloned into
pUC 18 and verified by sequencing [9].
Competitive PCR
Competitive PCR was performed as described by Gilliland,
Perrin and Bunn [15]. A master mix containing primers, PCR
buffer, Taq polymerase (Perkin Elmer/Cetus, Norwalk, CT, USA)
and an appropriate amount of eDNA was prepared. Ten micro-
liters of the competitive template at various concentrations were
DM
Fig. 2. Southern blot of amplified sequences by competitive PCR. Upper
bands (474 bp) were amplified from the authentic TGF-f31. Lower bands
(335 bp) were amplified from the mutant TGF-f31 template. The starting
concentrations of competitive mutant template in each tube (left to right)
were 8, 6, 4, 2, 1, 0.5 fg in normal glomeruli (Normal) and 36, 30, 24, 18,
12, 6 fg in glomeruli of diabetic patients (DM), respectively.
added to 90 J of the above mixture. The mixture was overlaid
with mineral oil and then amplified with the Perkin-Elmer/Cetus
thermal cycler. The amplification profile was the following: dena-
turation at 95°C for one minute, primer annealing at 65°C for 30
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seconds and extension at 72°C for one minute. After 40 amplifi-
cation cycles, an aliquot of each sample was digested with EcoRI
and run on a 2% NuSieve/agarose gel (FMC Bioproducts, Rock-
land, ME, USA). To exclude eDNA contamination, total RNA
was directly amplified with 1 pg of 13-actin mutant template or I fg
of TGF-f31 mutant template. No authentic bands were observed
when the total RNA was directly amplified.
The amount of glomerular /3-actin eDNA was determined by
densitometric analysis of ethidium bromide staining intensity.
Southern blot hybridization
Southern blot analysis was used to determine the amount of
glomerular TGF-/31 eDNA. DNA underwent electrophoresis,
denaturation and transfer to a Hybond-N+ filter (Amersham).
After drying at 80°C for two hours, the filters were prehybridized
in 6 X SSC, 10 x Denhardt's solution, 1% SDS and 50 sg/ml
salmon sperm DNA at 42°C for three hours. They were then
hybridized with a oligonucleotide probe (GGTAGTGAACCCG-
TTGATGTCCACTTGCA) that had been 5' end labeled with
[y-32P] ATP. This probe was complementary to sequence of exon
4 and 5 of the TGF-131 gene. The filters were hybridized at 37°C
overnight, washed with 6 X SSC and 0.1% SDS at room temper-
ature three times for 10 minutes and at 60°C for 30 minutes. After
exposure to Kodak X-Omat film (Eastman Kodak Co., Rochester,
NY, USA), the amount of cDNA was analyzed by densitometry.
We performed competitive PCR on 10 samples on five different
days and found interassay variation that was consistently below
15%.
Statistical analysis
To compare means among more than two groups, but the
underlying distribution was not assumed to hold normal, a mul-
tiple comparison test for a nonparametric, the Kruskal-Wallis test
was used. When the average ranks of the groups were judged
unequal by the test, the Dunn procedure was followed for a
comparison of specific groups. All data were expressed as the
median (25th percentile, 75th percentile). Correlations were
assessed by linear regression analysis. P value < 0.05 was consid-
ered to be statistically significant.
Results
Quantitative analysis of intraglomerular TGF-/31 in patients with
diabetes mellitus
The initial competitive PCR allowed us to determine the
amount of intraglomerular /3-actin eDNA. We found that the
levels of intraglomerular /3-actin eDNA were significantly higher
in the patients with diabetic nephropathy [13.4 (7.7, 16) pg/
glomerulus] than in the normal glomeruli [7.2 (4.2, 11.5) pg/
glomerulus; P < 0.0011. Therefore, we should adjust the samples
to equal concentrations of J3-actin cDNA. We used samples
containing 8 pg of 13-actin eDNA to determine the amount of
intraglomerular TGF-f31 mRNA. We again performed competi-
tive PCR by co-amplifying the mutant templates of TGF-/31.
Figure 2 shows the representative result of competitive PCR in
normal glomeruli and glomeruli obtained from patients with
diabetes mellitus. Raising amounts of the mutant TGF-/31 cDNA
increasingly inhibited amplification of authentic TGF-131 eDNA.
The ratio of mutant to authentic band density was calculated.
Levels of intraglomerular TGF-/31 mRNA were significantly
elevated in patients with diabetes mellitus as compared with levels
in normal glomeruli [0.75 (0.4, 1.33) fg/pg 13-actin vs. 0.2 (0.13,
0.36) fg/pg /3-actin, P < 0.001]. Patients were divided into three
groups according to their excretion of urinary albumin: 13 patients
with normoalbuminuria, 7 patients with microalbuminuria (> 15
.Lg/min), and 9 patients with overt albuminuria (> 200 gImin)
[16]. The amounts of intraglomerular TGF-/31 mRNA in patients
with normoalbuminuria, microalbuminuria and overt albuminuria
were 0.50 (0.40, 1.00), 1.00 (1.00, 1.88), 0.73 (0.39, 1.39) fglpg
13-actin, respectively. TGF-/31 mRNA levels were significantly
elevated in patients from all groups compared to normal glomer-
uli (Fig. 3). Patients were also divided into three groups based on
the extent of mesangial expansion seen on renal biopsy (Diffuse I
to Diffuse III). The amounts of intraglomerular TGF-J31 mRNA
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Fig. 3. Levels of intraglomerular TGF-131 mRNA and urina,y albumin
excretion. *<0.01, **<0.005, ***<0.001. Patientswere divided into
three groups according to their excretion of urinary albumin: patients with
normoalbuminuria (normo), patients with microalbuminuria (micro), and
patients with overt albuminuria (overt).
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Fig. 4. Levels of intraglomerular TGF-f31 mRNA and the extent of mesang-
ial expansion in renal biopsy. **p < 0.005. Patients were divided into three
groups based on the extent of mesangial expansion seen on renal biopsy.
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Fig. 5. immunohistochemical localization of
collagen type IV Positive immunostaining for
collagen type IV was observed in the
mesangium, glomerular basement membrane,
and Bowman's capsule (X 400).
in the Diffuse I, the Diffuse II and the Diffuse Ill group were 0.88
(0.40, 1.07), 0.7 (0.5, 1.5), and 0.75 (0.30, 1.32) fglpg /3-actin,
respectively. TGF-J31 mRNA levels were significantly elevated in
patients from all groups compared to normal glomeruli (Fig. 4).
These results indicate that high levels of glomerular TGF-/31
mRNA can be observed even in the early stage of diabetic
nephropathy.
Correlation between glomerular TGF-f31 mRNA and staining
intensity of collagen type IV
To examine the correlationship between the levels of intraglo-
merular TGF-/31 mRNA and collagen type IV synthesis, we
performed immunostaining with anti-collagen type IV in 27
patients with diabetic nephropathy. Positive immunostaining for
collagen type IV was observed in the mesangium, glomerular
basement membrane, and Bowman's capsule (Fig. 5). The levels
of intraglomerular TGF-131 mRNA were positively correlated
with the staining intensity of collagen type IV (Fig. 6).
Immunohistochemical localization of TGF-J31 in
diabetic nephropathy
To elucidate the production of TGF-f31 protein in glomeruli, we
performed immunostaining with anti-TGF-/31. Frozen sections
were obtained from 7 patients with diabetes mellitus (patient
number 3, 4, 7, 17, 21, 24, 28 in Table 1). Control specimens were
obtained from five patients with renal cell cancer. Positive staining
were observed in the mesangial area as shown in Figure 7. All of
the glomeruli from the seven patients with diabetes mellitus were
strongly positive for TGF-/31, whereas glomeruli from the control
specimens showed only trace staining. The staining were negative
when the primary antibody was preabsorbed with purified
TGF-p1 or when the tissues were incubated with the secondary
antibody alone.
Correlation between glomerular TGF-f31 mRNA and
clinical parameters
Next, we investigated correlation between intraglomerular
TGF-/31 mRNA and several clinical parameters. Values for
0
0 I I I I
Grade I Grade II Grade III
Fig. 6. Correlation between levels of intragloinerular TGF-/31 mRNA and
the staining intensity of collagen type IV The levels of intraglomerular
TGF-J31 mRNA were positively correlated with the staining intensity of
collagen type IV.
intraglomerular TGF-/31 mRNA correlated well with HbAlc
values (r = 0.65, p < 0.001; Fig. 8). However, values for
glomerular TGF-/31 mRNA levels did not correlate with values
for other clinical parameters such as urinary albumin excretion,
urinary /32 microglobulin excretion, urinary NAG excretion nor
endogenous serum creatinine. In addition, no correlation was
found with the following parameters: presense of hypertension or
hyperlipidemia, and duration of disease.
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Fig. 7. Confacal laser micrograph of a
glomendus from diabetes stained with anti-TGF-
j31. Positive staining was observed in the
mesangium (x 400).
a competitive PCR method. Previous studies have shown that
TGF-f31 protein and mRNA are mainly observed in mesangial
area [5, 17, 18], Thercfore, TGF-p1 is thought to be mainly
produced by mesangial cells in glomeruli.
TGF-pl functions in tissue repair by stimulating the synthesis of
extracellular matrix and also inhibiting its degradation [19, 20].
However, overproduction of TGF-f31 can lead to fibrosis via the
pathologic accumulation of cxtracellular matrix [17]. Isaka et al
have shown that introduction of the TGF-f31 gene into glomerular
cells induces mesangial matrix expansion in vivo [211. Border et al
have demonstrated that inhibition of TGF-/31 activity prevents the
accumulation of the mesangial matrix in antithymocyte serum-I induced glomerulonephritis [22, 23]. Several studies have shown
3.0 3,5 that TGF-1 is closely associated with mesangial matrix increase
in diabetic rat, mouse and human glomeruli [5—7, 24—311. These
previous reports suggest that TGF-j31 may be a main determinant
of mesangial expansion observed in diabetic nephropathy. How-
ever, the prior data in cell culture, animal experiments and human
tissue analysis have all focused on insulin-dependent diabetes
mellitus (IDDM). We have speculated the same association
between TGF-f31 and diabetic nephropathy due to NIDDM. We
found that significantly higher levels of intraglomerular TGF-f31
mRNA were observed in patients with NIDDM and intraglomeru-
lar TGF-f31 mRNA levels were elevated even in the early stage of
diabetic nephropathy. In addition, TGF-f31 protein was localized
in the glomeruli of patients with NIDDM, Accordingly, it is
conceivable that overproduction of TGF-131 in glomeruli is asso-
ciated with the initiation and progression of diabetic nephropathy
due to NIDDM as well as IDDM.
TOF-pi is secreted as a biologically latent form. Therefore,
TOP-/fl mRNA levels may not parallel TGF-/31 activity. In this
study, intraglomerular levels of TGF-/31 mRNA were correlated
with the amounts of glomerular collagen type IV. As mature
TGF-/31, which is functionally active, induces collagen type IV
synthesis in cultured mesangial cells [26, 31], this result provides
the indirect evidence that latent TGF-J31 is activated in the
glomeruli of the patients with diabetic nephropathy.
Shankland and Scholey have demonstrated that TGF-J31 ex-
pression increases in glomeruli in the early phase of renal
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Fig. 8. Corelation between levels of intraglomerular TGF-f31 mRNA and
HbAlc, Values for intraglomerular TGF-/31 mRNA correlated well with
HbAlc values.
Quantifying the expression of mRNA can provide important
information about protein levels and thus biological activity. We
used competitive PCR to measure the expression of intraglomeru-
lar TGF-/31 mRNA in patients with diabetic nephropathy. This
procedure uses a competitive mutant template of the same
sequence as the target except for the addition of a restriction site
by a single base substitution. Accordingly, differences in amplifi-
cation efficiency should be negligible. However, there are two
other significant problems in quantitating the intraglomerular
expression of mRNA; a difficulty in quantitating the amount of
total RNA and an inconsistency in the efficiency of reverse
transcription. To circumvent these probrems, we first quantified
the amounts of mRNA expression of the "housekeeping" gene,
/3-actin, and then diluted the samples so they contained equal
amounts of /3-actin eDNA.
Levels of glomerular TOP-/fl mRNA can be measured accu-
rately by a competitive PCR method. However, we cannot identify
which cells in glomeruli are responsible for TOF-/31 production by
Discussion
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hypertrophy and normalization of blood glucose levels with
insulin treatment attenuates the increase in TGF-/31 expression in
diabetic rats [32]. Strict glycemic control has been shown to
ameliorate the progression of human diabetic nephropathy [33].
The present study indicated that values for intraglomerular
TGF-/31 mRNA correlated well with HbAlc values. These data
suggest that glycemic control slow the progression of diabetic
nephropathy partly via the inhibition of TGF-/31 production in
glomeruli. To clarify the association between glycemic control and
the inhibition of TGF-f31 production, we should perform the
follow-up study and measure the intraglomerular TGF-pl mRNA
after strict glycemic control.
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